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enetic Testing in Subjects
ith No Clinical Abnormality
he Tip of a Huge Iceberg*
an M. Roden, MD
ashville, Tennessee
enetic testing for individuals with manifest long QT
yndrome (LQTS) has become part of routine care to
onfirm the clinical diagnosis and to stratify risk. A spinoff
f such testing has been the identification of proband
elatives with normal QT intervals who nevertheless are
utation carriers. A report in this issue of the Journal (1)
ddresses risk in this group. More generally, as described in
he following, we are on the precipice of very widespread
enetic testing using new sequencing approaches. The
resent study points to issues we will have to consider as we
ncreasingly identify subjects with genetic variants and no
linical abnormalities.
See page 51
The congenital LQTS was first recognized as a clinical
ntity in the late 1950s and the early 1960s. Over the next
decades it came to be characterized largely as a rare
ondition in which children, adolescents, and young adults
isplayed striking QT interval prolongation and suscepti-
ility to sudden death, generally with exercise, emotional
tress, or exposure to sudden loud noises; the incidence of
yncope or sudden death seemed to diminish with beta-
locker therapy (2). Exceptions to this general pattern were
oted, such as occasional subjects who died in their sleep or
ithout apparent provocation. The real breakthrough in
anagement arose from fundamental scientific discovery:
he identification of disease genes in which mutations cause
he congenital LQTS (3). Initial studies in relatively small
umbers of families were able to establish that the 3 major
ubtypes differ in electrocardiographic patterns, provokers of
rrhythmias, response to beta-blocker therapy, and even
rognosis (4,5). These advances in translating basic molec-
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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eported that he has no relationships to disclose.lar and genetic information to the care of patients were
nly possible with the aggregation of large numbers of
ffected patients and their families into large registries.
The last decade and a half has seen not only advances in
efining subtype-specific management, but also an increas-
ng awareness of the disease among cardiologists and inter-
ists, and the increasing availability of genetic testing. One
onsequence of these advances is the increasing recognition
f the phenomenon of incomplete penetrance (6), that is,
ubjects who are carriers of the causative mutation in a
ember of their family and yet who display normal elec-
rocardiographic results. Previous studies have demon-
trated that among those with prolonged QT intervals, the
reater the prolongation the worse the prognosis (7). Thus,
utation carriers with normal QT intervals ought to be at
ow risk. The present study supports that contention but
oes not totally erase risk in such subjects, raising new
uestions about management.
ummary of the Present Study
he new study reports the incidence of aborted cardiac
rrest (ACA) or sudden cardiac death (SCD) from birth
hrough age 40 years in 3,386 subjects from 552 families
rom U.S., Western European, and Japanese centers.
mong these subjects, 1,392 were mutation carriers with
ong QT intervals (defined here as a corrected QT [QTc]
nterval 440 ms), 469 were mutation carriers with QTc
nterval440 ms, and the remaining 1,525 family members
id not carry the proband’s mutation and had normal QT
ntervals. Among those with long QTc intervals, the risk for
CA or SCD was 15% over the 40 years of follow-up
about 209 events), compared with 4% (17 events) in
utation carriers with normal QT intervals and 0.4%
mong unaffected family member controls.
Previous studies have identified risk factors for ACA or
CD in those with long QTc intervals: female sex, non-
QTS type 1 (LQT1) genotype, longer QT intervals, and
as discussed further in the following) mutation location. In
his and previous studies, a family history of ACA or sudden
eath did not increase risk for these events in the study
ubjects. An interesting question is whether previous pre-
ictors of ACA or SCD also apply in mutation carriers with
ormal QTc intervals, and neither female sex nor QTc
uration did. In the present study group, the prognosis was
nexpectedly worse in those with LQT1; it is conceivable
hat the infrequent use of beta-blockers contributed (8).
In addition to specific genetic subtype (LQT1, LQT2, or
QT3), recent studies, using essentially the same study
ubjects as those reported here, have suggested that the
redicted functional properties of individual mutations may
e important in determining prognosis. Thus, for example,
n patients with LQT1 and in those with LQT2, the
ommon potassium channel-linked forms of the disease,
rognosis appeared to be more severe among those patients
ith mutations predicted to affect transmembrane segments
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December 28, 2010/January 4, 2011:60–2 Genetic Testing With No Clinical Abnormalityf the encoded channel protein, and less severe for muta-
ions predicted to affect N- or C-termini (9–11). One
ossibility is that mutations affecting transmembrane seg-
ents are more likely to disrupt the permeation pathway of
he channel (as suggested in the present report); more
enerally, mutations in transmembrane segments may be
ore likely to exert dominant negative effects in vitro, that
s, to suppress potassium current by more than the 50%
xpected from a “simple” autosomal dominant disease.
nterestingly, in the present study, this relationship of
ransmembrane versus N- or C-terminal mutations did not
old up in patients with manifest QT prolongation but did
ppear to be a predictor in those with normal QT intervals.
verall, there are fewer data available for LQT3 (the
odium channel-linked form of the disease), and although
ominant negative suppression of channel function has been
bserved in vitro (12), the mechanisms and extent of the
henomenon are not so well understood; variants of uncer-
ain significance seem more common in the cardiac sodium
hannel gene (SCN5A) than in the two potassium channel
enes (KCNQ1 and KCNH2) (13).
aveats to the Interpretation of the Present Study
he common criticism directed against registry studies in
ny setting is their observational nature; these are not
andomized clinical trials. However, randomized clinical
rials are very difficult to accomplish in a rare disease such as
he congenital LQTS because of the logistics that such an
ndertaking would require, the heterogeneous nature of the
isease (many mutations), and, importantly, the likely lack
f equipoise among large numbers of investigators around
he world. So, although the approach is imperfect, it is what
e have.
Given this limitation, it is appropriate to think a bit more
bout how mutation carriers with normal QTc intervals get
nto the registry and are followed. The study group was
ccumulated by several large registries, as well as a series of
maller centers across Europe. In this effort to be inclusive,
he investigators run the risk of introducing errors because
f differences in case ascertainment. This is particularly
ermane to the study group. For example, one could easily
nvision a situation in which a proband’s children are more
ikely to undergo genetic testing than the parents.
ollow-up and therapy for those with normal QTc intervals
ight be different from those with long QTc intervals;
edication histories are unavailable for some of the study
enters. Indeed, we do not know if a normal QTc interval
nce means a normal QTc interval on subsequent record-
ngs. Genetic ancestry plays a strong role in modulating risk
n other settings, and so inclusion of multiple racial
roups—desirable from a clinical point of view—may fur-
her confound interpretation of the study outcome.
Among the 469 mutation carriers with normal QTc
ntervals, there were 17 ACA or SCD events. Therefore, it
ould be very imprudent to draw sweeping management sonclusions on the basis of this small number and, in
articular, on the basis of subsets of this small number.
hus, for example, the investigators’ conclusion that prog-
osis may be worse with mutations in certain locations of
he channel protein must be tempered by the very small
umber of events.
Finally, some comment must be offered on the single
illustrative” case presented: a mutation carrier with com-
letely normal electrocardiographic results and episodes of
on–pause-dependent, non–heart rate change–dependent
olymorphic ventricular tachycardia. These tracings are
ypical of so-called idiopathic ventricular fibrillation initi-
ted from a single focus (note the identical morphology of
he initiating tachycardia beat) (14). Thus, this may well not
epresent a manifestation of LQTS; alternatively, this could
e a new manifestation of LQTS, but absent other supporting
ata (such as a demonstration of how the mutation could
enerate this rhythm in the absence of QT prolongation), this
s a difficult conclusion to support. The presentation of the
ntracardiac recordings adds further uncertainty. The top strip
n Figure 4C shows rapid ventricular tachycardia, but with a
elatively late coupled onset, unlike the clinical episodes pre-
ented. The bottom strip shows wide complex rhythm that is
ot a tachycardia, but rather simply atrioventricular pacing.
welling on a single case in an analysis of 3,386 subjects may
eem pointless until one recognizes that misclassification of
ven 1 or 2 of the 17 ACA or SCD events could easily refute
he conclusions of this study.
hat Is Needed Next?
enetic testing for the congenital LQTS, and many, many
ther conditions, is now beginning to be accepted into the
abric of modern health care. One naïve hope might be that
uch testing could be deterministic; that is, a genetic test
ould tell a clinician what to do in a given situation.
owever, as large datasets accrue relating genotypes to a
ariety of outcomes, the lesson that genetics is probabilistic
s being reinforced: genetic variation modulates susceptibil-
ty to important clinical phenotypes, such as ACA or SCD.
reasonable way forward, therefore, might be to simply
row the current databases in size and duration of follow-
p, but even with much larger study sets, genetics will never
ecome deterministic.
I cling, therefore, to the hope that understanding the
echanisms whereby individual mutations cause channel
ysfunction, and more importantly how common and rare
enetic variants and the environment conspire to modulate
hose clinical phenotypes, is more likely to provide us with
irections about how to manage vexing patients. The
omparison of transmembrane versus nontransmembrane
utations is a wonderful start, but surely this must be
ollowed by more detailed exploration of individual muta-
ions and the channel dysfunction they confer. Recent
tudies describing the role of variation in the NOS1AP gene
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Genetic Testing With No Clinical Abnormality December 28, 2010/January 4, 2011:60–2s a potential modifier of risk highlight the potential of
echanistic approaches (15,16).
What should a physician do with mutation-positive patients
ith normal QT intervals? I am inclined to suggest following
hese individuals with serial electrocardiograms, avoiding QT-
rolonging drugs, and deploying beta-blockers. I do not think
he data on mutation location are robust enough to make this
art of clinical decision-making yet.
The issue of genetic testing in individuals with no apparent
henotype is a general problem in modern genomics. Current
stimates, derived from “next-generation” sequencing of whole
uman genomes, are that each of us harbors tens of thousands
f deoxyribonucleic acid (DNA) variants that are present only
n us and our immediate families (17), and that hundreds of
hese “personal” DNA variants are nonsynonymous, that is,
hey are predicted to alter amino acid sequence (18). As an
xample, the fully annotated genome of Steven Quake (a
ounder of Helicos, one of the companies developing next-
eneration DNA sequencing hardware) was published earlier
his year (19). The Quake genome included 3 rare variants, in
yosin-binding protein C, desmoplakin, and TMEM43, that
ould predispose to an increased risk for SCD. Whether
ariants such as these, discovered in an asymptomatic subject
although Quake actually has a family history of SCD), are
iologically important or merely incidental findings is very
uch up in the air (20). This highlights the potential advan-
ages and drawbacks of a vision of future health care in which
hole genome sequences are included pre-emptively as part of
ach patient’s medical record. It is possible that this approach
ill discover polymorphisms that are actionable, but the
ownside is a very high likelihood that many variants will be
argely irrelevant.
Interventional cardiology continues to struggle with the
culostenotic reflex – the overwhelming urge to do some-
hing about an abnormality even in the absence of evidence
hat an intervention will be beneficial (21). One conclusion
draw from the present study is that we need more data
and ultimately guidelines) to address the management of
atients with genetic variants and no detected clinical
bnormalities. Otherwise, we will generate a 21st century
quivalent of the oculostenotic reflex whose implications for
ealth care may be enormous.
eprint requests and correspondence: Dr. Dan M. Roden,
anderbilt University School of Medicine, 1285 Medical Research
uilding IV, Nashville, Tennessee 37232. E-mail: dan.roden@
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